TEVA logo

TEVA Cash From Financing

Annual CFF

-$1.79 B
+$122.00 M+6.38%

December 31, 2024


Summary


Performance

TEVA Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherTEVAcash flowmetrics:

Quarterly CFF

-$674.00 M
-$674.00 M-100.00%

December 31, 2024


Summary


Performance

TEVA Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherTEVAcash flowmetrics:

TTM CFF

-$1.79 B
-$98.00 M-5.79%

December 31, 2024


Summary


Performance

TEVA TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherTEVAcash flowmetrics:

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

TEVA Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+6.4%-346.4%-31.9%
3 y3 years+17.5%-99.4%+11.1%
5 y5 years+7.0%-439.2%+5.0%

TEVA Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-20.4%+17.5%<-9999.0%+30.2%-40.3%+21.1%
5 y5-year-20.4%+17.5%<-9999.0%+42.7%-40.3%+26.5%
alltimeall time-107.1%+68.8%-102.7%+73.1%-105.8%+70.5%

Teva Pharmaceutical Industries Limited Cash From Financing History

DateAnnualQuarterlyTTM
Dec 2024
-$1.79 B(-6.4%)
-$674.00 M(<-9900.0%)
-$1.79 B(+5.8%)
Sep 2024
-
$0.00(-100.0%)
-$1.69 B(-25.4%)
Jun 2024
-
-$966.00 M(+539.7%)
-$2.27 B(+67.1%)
Mar 2024
-
-$151.00 M(-73.8%)
-$1.36 B(-29.0%)
Dec 2023
-$1.91 B(+28.6%)
-$576.00 M(0.0%)
-$1.91 B(-6.6%)
Sep 2023
-
-$576.00 M(+947.3%)
-$2.05 B(+7.1%)
Jun 2023
-
-$55.00 M(-92.2%)
-$1.91 B(-12.9%)
Mar 2023
-
-$706.00 M(-0.7%)
-$2.19 B(+47.6%)
Dec 2022
-$1.49 B(-31.5%)
-$711.00 M(+61.6%)
-$1.49 B(+16.4%)
Sep 2022
-
-$440.00 M(+30.2%)
-$1.28 B(-36.6%)
Jun 2022
-
-$338.00 M(<-9900.0%)
-$2.01 B(+20.1%)
Mar 2022
-
$2.00 M(-100.4%)
-$1.68 B(-22.8%)
Dec 2021
-$2.17 B(+15.2%)
-$501.00 M(-57.4%)
-$2.17 B(+20.9%)
Sep 2021
-
-$1.18 B(>+9900.0%)
-$1.80 B(+7.2%)
Jun 2021
-
-$1.00 M(-99.8%)
-$1.68 B(-0.1%)
Mar 2021
-
-$493.00 M(+294.4%)
-$1.68 B(-11.0%)
Dec 2020
-$1.89 B(-2.1%)
-$125.00 M(-88.2%)
-$1.89 B(-5.8%)
Sep 2020
-
-$1.06 B(>+9900.0%)
-$2.00 B(-16.8%)
Jun 2020
-
-$3.00 M(-99.6%)
-$2.40 B(-1.3%)
Mar 2020
-
-$700.00 M(+190.5%)
-$2.44 B(+26.5%)
Dec 2019
-$1.93 B(-42.5%)
-$241.00 M(-83.5%)
-$1.93 B(-11.8%)
Sep 2019
-
-$1.46 B(+4074.3%)
-$2.18 B(+52.9%)
Jun 2019
-
-$35.00 M(-81.5%)
-$1.43 B(-1.4%)
Mar 2019
-
-$189.00 M(-62.1%)
-$1.45 B(-56.8%)
Dec 2018
-$3.35 B(-41.7%)
-$499.00 M(-29.2%)
-$3.35 B(-37.5%)
Sep 2018
-
-$705.00 M(+1158.9%)
-$5.36 B(-2.2%)
Jun 2018
-
-$56.00 M(-97.3%)
-$5.48 B(-9.8%)
Mar 2018
-
-$2.09 B(-16.6%)
-$6.07 B(+5.6%)
Dec 2017
-$5.75 B(-122.8%)
-$2.51 B(+203.8%)
-$5.75 B(+45.8%)
Sep 2017
-
-$825.00 M(+26.7%)
-$3.94 B(-117.7%)
Jun 2017
-
-$651.00 M(-63.2%)
$22.25 B(-4.0%)
Mar 2017
-
-$1.77 B(+152.2%)
$23.18 B(-8.1%)
Dec 2016
$25.22 B(+424.8%)
-$701.00 M(-102.8%)
$25.22 B(-17.7%)
Sep 2016
-
$25.37 B(+8993.9%)
$30.63 B(+634.4%)
Jun 2016
-
$279.00 M(+4.5%)
$4.17 B(-16.2%)
Mar 2016
-
$267.00 M(-94.3%)
$4.98 B(+3.6%)
Dec 2015
$4.80 B(-302.3%)
$4.71 B(-532.6%)
$4.80 B(-1055.3%)
Sep 2015
-
-$1.09 B(-200.3%)
-$503.00 M(-295.0%)
Jun 2015
-
$1.09 B(+1068.8%)
$258.00 M(-115.7%)
Mar 2015
-
$93.00 M(-115.7%)
-$1.65 B(-30.6%)
Dec 2014
-$2.38 B(-38.8%)
-$593.00 M(+80.2%)
-$2.38 B(-1.1%)
Sep 2014
-
-$329.00 M(-59.8%)
-$2.40 B(+3.1%)
Jun 2014
-
-$819.00 M(+29.2%)
-$2.33 B(+3.1%)
Mar 2014
-
-$634.00 M(+2.4%)
-$2.26 B(-41.9%)
Dec 2013
-$3.88 B(+131.4%)
-$619.00 M(+141.8%)
-$3.88 B(+29.5%)
Sep 2013
-
-$256.00 M(-65.8%)
-$3.00 B(-9.5%)
Jun 2013
-
-$748.00 M(-66.9%)
-$3.31 B(-0.4%)
Mar 2013
-
-$2.26 B(-949.6%)
-$3.33 B(+98.2%)
Dec 2012
-$1.68 B(-150.3%)
$266.00 M(-146.7%)
-$1.68 B(-178.1%)
Sep 2012
-
-$570.00 M(-25.1%)
$2.15 B(-37.1%)
Jun 2012
-
-$761.00 M(+24.1%)
$3.42 B(-2.2%)
Mar 2012
-
-$613.00 M(-115.0%)
$3.49 B(+4.7%)
Dec 2011
$3.34 B
$4.09 B(+486.2%)
$3.34 B(-351.0%)
DateAnnualQuarterlyTTM
Sep 2011
-
$698.00 M(-202.0%)
-$1.33 B(-40.4%)
Jun 2011
-
-$684.00 M(-11.2%)
-$2.23 B(>+9900.0%)
Mar 2011
-
-$770.00 M(+34.4%)
-$22.00 M(-103.8%)
Dec 2010
$573.00 M(-125.3%)
-$573.00 M(+180.9%)
$573.00 M(-38.6%)
Sep 2010
-
-$204.00 M(-113.4%)
$933.00 M(+288.8%)
Jun 2010
-
$1.52 B(-971.4%)
$240.00 M(-109.9%)
Mar 2010
-
-$175.00 M(-17.8%)
-$2.42 B(+6.7%)
Dec 2009
-$2.27 B(-266.8%)
-$213.00 M(-76.3%)
-$2.27 B(+2444.9%)
Sep 2009
-
-$897.00 M(-20.7%)
-$89.00 M(-112.3%)
Jun 2009
-
-$1.13 B(+4612.5%)
$724.00 M(-40.8%)
Mar 2009
-
-$24.00 M(-101.2%)
$1.22 B(-10.0%)
Dec 2008
$1.36 B(-475.1%)
$1.96 B(-2436.9%)
$1.36 B(-278.4%)
Sep 2008
-
-$84.00 M(-86.7%)
-$761.00 M(-17.3%)
Jun 2008
-
-$633.00 M(-665.2%)
-$920.00 M(+221.7%)
Mar 2008
-
$112.00 M(-171.8%)
-$286.00 M(-21.0%)
Dec 2007
-$362.00 M(-117.9%)
-$156.00 M(-35.8%)
-$362.00 M(-31.9%)
Sep 2007
-
-$243.00 M(<-9900.0%)
-$531.30 M(-1.9%)
Jun 2007
-
$1.00 M(-97.2%)
-$541.80 M(+3.2%)
Mar 2007
-
$36.00 M(-111.1%)
-$525.00 M(-125.9%)
Dec 2006
$2.02 B(-746.6%)
-$325.30 M(+28.3%)
$2.02 B(-25.0%)
Sep 2006
-
-$253.50 M(-1524.2%)
$2.70 B(-3.5%)
Jun 2006
-
$17.80 M(-99.3%)
$2.80 B(+8.3%)
Mar 2006
-
$2.58 B(+636.9%)
$2.58 B(-924.8%)
Dec 2005
-$313.00 M(-136.7%)
$350.80 M(-323.9%)
-$313.00 M(-59.1%)
Sep 2005
-
-$156.70 M(-20.6%)
-$764.40 M(+6.9%)
Jun 2005
-
-$197.40 M(-36.3%)
-$714.80 M(+31.2%)
Mar 2005
-
-$309.70 M(+207.9%)
-$544.80 M(-163.9%)
Dec 2004
$852.00 M(+2778.4%)
-$100.60 M(-6.1%)
$852.00 M(-13.6%)
Sep 2004
-
-$107.10 M(+290.9%)
$986.60 M(-8.7%)
Jun 2004
-
-$27.40 M(-102.5%)
$1.08 B(-2.5%)
Mar 2004
-
$1.09 B(+3097.4%)
$1.11 B(+3643.6%)
Dec 2003
$29.60 M(-91.2%)
$34.00 M(-361.5%)
$29.60 M(-93.1%)
Sep 2003
-
-$13.00 M(<-9900.0%)
$428.20 M(+0.8%)
Jun 2003
-
$0.00(-100.0%)
$424.70 M(+7.4%)
Mar 2003
-
$8.60 M(-98.0%)
$395.50 M(+17.2%)
Dec 2002
$337.50 M(+26.5%)
$432.60 M(-2721.8%)
$337.50 M(-409.7%)
Sep 2002
-
-$16.50 M(-43.5%)
-$108.98 M(-131.5%)
Jun 2002
-
-$29.20 M(-40.9%)
$345.47 M(+1.9%)
Mar 2002
-
-$49.40 M(+255.8%)
$339.11 M(+27.1%)
Dec 2001
$266.72 M(+0.4%)
-$13.88 M(-103.2%)
$266.72 M(-4.9%)
Sep 2001
-
$437.95 M(-1331.5%)
$280.60 M(-278.3%)
Jun 2001
-
-$35.56 M(-70.8%)
-$157.35 M(+29.2%)
Mar 2001
-
-$121.79 M
-$121.79 M
Dec 2000
$265.71 M(+75.4%)
-
-
Dec 1999
$151.48 M(+174.6%)
-
-
Dec 1998
$55.16 M(-141.0%)
-
-
Dec 1997
-$134.50 M(-202.5%)
-
-
Dec 1996
$131.20 M(+226.4%)
-
-
Dec 1995
$40.20 M(+0.8%)
-
-
Dec 1994
$39.90 M(-10.5%)
-
-
Dec 1993
$44.60 M(+85.8%)
-
-
Dec 1992
$24.00 M(-31.8%)
-
-
Dec 1991
$35.20 M
-
-

FAQ

  • What is Teva Pharmaceutical Industries Limited annual cash flow from financing activities?
  • What is the all time high annual CFF for Teva Pharmaceutical Industries Limited?
  • What is Teva Pharmaceutical Industries Limited annual CFF year-on-year change?
  • What is Teva Pharmaceutical Industries Limited quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Teva Pharmaceutical Industries Limited?
  • What is Teva Pharmaceutical Industries Limited quarterly CFF year-on-year change?
  • What is Teva Pharmaceutical Industries Limited TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Teva Pharmaceutical Industries Limited?
  • What is Teva Pharmaceutical Industries Limited TTM CFF year-on-year change?

What is Teva Pharmaceutical Industries Limited annual cash flow from financing activities?

The current annual CFF of TEVA is -$1.79 B

What is the all time high annual CFF for Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited all-time high annual cash flow from financing activities is $25.22 B

What is Teva Pharmaceutical Industries Limited annual CFF year-on-year change?

Over the past year, TEVA annual cash flow from financing activities has changed by +$122.00 M (+6.38%)

What is Teva Pharmaceutical Industries Limited quarterly cash flow from financing activities?

The current quarterly CFF of TEVA is -$674.00 M

What is the all time high quarterly CFF for Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited all-time high quarterly cash flow from financing activities is $25.37 B

What is Teva Pharmaceutical Industries Limited quarterly CFF year-on-year change?

Over the past year, TEVA quarterly cash flow from financing activities has changed by -$523.00 M (-346.36%)

What is Teva Pharmaceutical Industries Limited TTM cash flow from financing activities?

The current TTM CFF of TEVA is -$1.79 B

What is the all time high TTM CFF for Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited all-time high TTM cash flow from financing activities is $30.63 B

What is Teva Pharmaceutical Industries Limited TTM CFF year-on-year change?

Over the past year, TEVA TTM cash flow from financing activities has changed by -$433.00 M (-31.89%)